197 related articles for article (PubMed ID: 23551925)
1. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
Flint A; Kapitza C; Zdravkovic M
Diabetes Obes Metab; 2013 Oct; 15(10):958-62. PubMed ID: 23551925
[TBL] [Abstract][Full Text] [Related]
2. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
Horowitz M; Flint A; Jones KL; Hindsberger C; Rasmussen MF; Kapitza C; Doran S; Jax T; Zdravkovic M; Chapman IM
Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
[TBL] [Abstract][Full Text] [Related]
3. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
van Can J; Sloth B; Jensen CB; Flint A; Blaak EE; Saris WH
Int J Obes (Lond); 2014 Jun; 38(6):784-93. PubMed ID: 23999198
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
[TBL] [Abstract][Full Text] [Related]
5. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
[TBL] [Abstract][Full Text] [Related]
7. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
8. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
9. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.
Schmidt JB; Gregersen NT; Pedersen SD; Arentoft JL; Ritz C; Schwartz TW; Holst JJ; Astrup A; Sjödin A
Am J Physiol Endocrinol Metab; 2014 Jun; 306(11):E1248-56. PubMed ID: 24735885
[TBL] [Abstract][Full Text] [Related]
10. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
[TBL] [Abstract][Full Text] [Related]
11. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
[TBL] [Abstract][Full Text] [Related]
12. Appetite hormones and energy intake in obese men after consumption of fructose, glucose and whey protein beverages.
Bowen J; Noakes M; Clifton PM
Int J Obes (Lond); 2007 Nov; 31(11):1696-703. PubMed ID: 17593904
[TBL] [Abstract][Full Text] [Related]
13. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.
Kapitza C; Zdravkovic M; Hindsberger C; Flint A
Adv Ther; 2011 Aug; 28(8):650-60. PubMed ID: 21792552
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
15. Flaxseed dietary fibers suppress postprandial lipemia and appetite sensation in young men.
Kristensen M; Savorani F; Christensen S; Engelsen SB; Bügel S; Toubro S; Tetens I; Astrup A
Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):136-43. PubMed ID: 21802266
[TBL] [Abstract][Full Text] [Related]
16. Postprandial effects of a polyphenolic grape extract (PGE) supplement on appetite and food intake: a randomised dose-comparison trial.
Shin HS; Kindleysides S; Yip W; Budgett SC; Ingram JR; Poppitt SD
Nutr J; 2015 Sep; 14():96. PubMed ID: 26370656
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint A; Raben A; Astrup A; Holst JJ
J Clin Invest; 1998 Feb; 101(3):515-20. PubMed ID: 9449682
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
20. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
